Related Experiment Videos
[Clinical evaluation of aspoxicillin in children]
Abstract:
Aspoxicillin (ASPC), a new penicillin for injection, was evaluated for its efficacy and safety in 29 children with bacterial infection (Table 1), and the following results were obtained. MICs of ASPC to 26 strains of isolated organisms are shown in Table 2. MICs to 4 out of 13 strains of H. influenzae were higher than 6.25 micrograms/ml. MICs to 5 strains of S. pneumoniae were lower than 0.78 microgram/ml and 1 out of 3 strains of S. aureus and 1 strain of E. coli showed higher MICs than 100 micrograms/ml. ASPC was administered in 3 or 4 divided doses at a daily dosage ranging from 21 to 98 mg/kg by 30 minutes drip infusion or intravenous injection to 29 patients (16 cases of pneumonia, 8 cases of tonsillitis, 3 cases of bronchitis, 1 case of urinary tract infection, 1 case of impetigo) and the following clinical results were obtained: excellent; 11 cases, good; 11 cases, fair; 3 cases, poor; 1 case. The overall efficacy rate was 85% (Table 3, 4). No clinical side-effects were observed in any of the patients. Leukopenia was noted in 1 case. Slight elevation of GOT and GPT was noted in 2 cases, and minimal elevation of GOT was observed in other 2 cases (Table 5). These data suggest that ASPC is an useful new antibiotic in the treatment of children with susceptible bacterial infection and may be used as the first choice antibiotic for the treatment of respiratory tract infection in children.
Insights
Aspoxicillin (ASPC) is a new penicillin effective against bacterial infections in children, showing an 85% efficacy rate with minimal side effects. It is a promising first-choice antibiotic for pediatric respiratory tract infections.
Area of Science:
- Pharmacology
- Pediatrics
- Infectious Diseases
Context:
- Bacterial infections pose a significant health risk to children.
- New antibiotic options are crucial for combating resistant pathogens.
- Penicillin-class antibiotics remain a cornerstone of antibacterial therapy.
Purpose:
- To evaluate the efficacy and safety of Aspoxicillin (ASPC) in pediatric patients.
- To determine the antimicrobial spectrum of ASPC against common respiratory pathogens.
- To assess the clinical outcomes and adverse events associated with ASPC treatment in children.
Summary:
- Aspoxicillin (ASPC) demonstrated an 85% overall efficacy rate in treating 29 children with various bacterial infections, including pneumonia and tonsillitis.
- Minimum inhibitory concentrations (MICs) indicated ASPC's activity against *Streptococcus pneumoniae* but variable activity against *Haemophilus influenzae*, *Staphylococcus aureus*, and *Escherichia coli*.
- No significant clinical side-effects were reported, with only one case of leukopenia and mild, transient elevations in liver enzymes (GOT, GPT) observed.
Impact:
- ASPC shows promise as a safe and effective antibiotic for treating susceptible bacterial infections in children.
- The findings suggest ASPC may be a valuable first-line treatment option for pediatric respiratory tract infections.
- Further research could explore ASPC's role in managing other pediatric bacterial infections and its comparative effectiveness against existing therapies.